
Digital Pharma: A Year in Digital (2/5)
pharmafile | December 10, 2009 | Feature | Medical Communications |Â Â 2009, GSK, digi, digital pharma, year in reviewÂ
Favourite use of digital (pharma)
Creative Lynx & Jansen-Cilag’s Concerta XL Tablet PC campaign
Favourite use of digital (non-pharma)
BBC iPlayer
Favourite social media initiative (pharma)
Boehringer and Twitter – a brave step forwards for pharma in a new channel
Favourite social media initiative (non-pharma)
Twitter – a brilliant way to share and collaborate but in a small space. Makes people cut out the waffle 😉
Most significant online event for pharma in 2009
The FDA social media event – for getting them to discuss openly
How would you summarise pharma’s use of ‘digital’ in 2009
A lot of the activities are very ‘same-old-stuff’, but a few companies pushed the boundaries in trying new channels.
A good leap forwards for those prepared to try!
Kai Gait is digital commerce marketing manager at GlaxoSmithKline. He is involved in developing innovative digital strategies and tools to engage with healthcare customers. Kai and the Digital Commerce team were recently behind the GSK UK product information website, health.gsk.co.uk.
Over the next week some of European pharma’s foremost digital exponents have kindly agreed to share their online highlights from the year. The series continues on Monday with Roche’s head of corporate internet and social media Sabine Kostevc.
Related Content

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis
GSK’s Exdensur (depemokimab), a twice-yearly biological medicine, has received approval from the UK Medicines and …

Multiple myeloma treatment approved in Japan
GSK’s Blenrep (belantamab mafodotin) combinations have been approved by Japan’s Ministry of Health, Labour and …

US FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit
PHILADELPHIA–GSK plc today announced the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) in combination …






